Open AccessThe Effect of Ursodeoxycholic acid and N-acetyl cysteine on Lymphoblast Viability
Author(s) -
Ali Ayçiçek,
Tuba Nur Tahtakesen,
Cengiz Bayram
Publication year - 2022
Publication title -
basic and clinical cancer research
Language(s) - English
Resource type - Journals
eISSN - 2228-6527
pISSN - 2228-5466
DOI - 10.18502/bccr.v13i1.8829
Subject(s) - lymphoblast , viability assay , incubation , ursodeoxycholic acid , medicine , interquartile range , in vivo , ex vivo , acute lymphocytic leukemia , in vitro , transplantation , flow cytometry , leukemia , chemistry , andrology , immunology , pharmacology , lymphoblastic leukemia , biochemistry , biology , cell culture , genetics , microbiology and biotechnology
Aim: To investigate invitro ursodeoxycholic acid (UDCA) and N-acetyl cysteine (NAC) effect on blast cell viability in children newly diagnosed with acute lymphoblastic leukemia (ALL).
Patients and Methods: Samples were obtained from 52 newly diagnosed ALL patients aged 1 to 17 years. UDCA and NAC were added at clinically relevant concentrations (0-300 micrograms) onto 5x10^5 cells treated at room temperature in a dark place. Untreated and treated cells were stained with 7-amino-actinomycin D (7AAD PE) and analyzed by flow cytometry
Results: Median (interquartile range; IQR) blast percentage and incubation time were 90% (11) and 18 (1.5) hours, respectively. The dead/live blast cells ratio (7AAD+) was lower in lymphoblasts treated with all NAC concentrations than untreated controls (P 0.05). There was also no correlation between different doses of UCDA and NAC regarding blast cell viability (P > 0.232).
Conclusion: The present study showed that in vitro NAC use had a protective effect on lymphoblast viability in newly diagnosed ALL patients before starting chemotherapy. Patient-derived ALL cells can be successfully analyzed ex vivo in a short and different period without loss of blasts.